Banque Transatlantique Sa Janux Therapeutics, Inc. Transaction History
Banque Transatlantique Sa
- $5.69 Billion
- Q1 2025
A detailed history of Banque Transatlantique Sa transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Banque Transatlantique Sa holds 42 shares of JANX stock, worth $1,059. This represents 0.0% of its overall portfolio holdings.
Number of Shares
42Holding current value
$1,059% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding JANX
# of Institutions
194Shares Held
57.3MCall Options Held
626KPut Options Held
155K-
Ra Capital Management, L.P. Boston, MA11.2MShares$282 Million6.27% of portfolio
-
Janus Henderson Group PLC London, X04.6MShares$116 Million0.07% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.65MShares$92.2 Million0.19% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY3.33MShares$84 Million4.61% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$59.1 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.05B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...